Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Breakthrough May Revolutionize Preclinical Imaging

By BiotechDaily International staff writers
Posted on 07 Oct 2013
Image: The magnetic particle imaging (MPI) system is an entirely new technology for preclinical imaging (Photo courtesy of Bruker).
Image: The magnetic particle imaging (MPI) system is an entirely new technology for preclinical imaging (Photo courtesy of Bruker).
A novel imaging technique for disease studies, translational research, and drug discovery will soon be made available to the biotechnology research community.

Bruker (Billerica, MA, USA) has announced the world’s first magnetic particle imaging (MPI) system, a novel technology for preclinical imaging. The MPI tomographic imaging technique relies on the detection of the magnetic properties of iron-oxide nanoparticles injected into the bloodstream to produce three-dimensional images. The system has been used to produce images that accurately captured the real-time physiological activity of a mouse's cardiovascular system,

The Bruker preclinical MPI scanner was developed in collaboration with Royal Philips (Amsterdam, The Netherlands), in a partnership that combined Bruker’s leadership in analytical magnetic resonance instruments with Philips’ strengths in medical imaging technology. The partners will co-market the preclinical MPI scanner.

Dr. Michael Heidenreich, technical director at Bruker, said, "We are very pleased about this breakthrough in preclinical imaging and our collaboration with Philips on this exciting technology. Magnetic particle imaging is a novel imaging modality that is expected to enable scientists to address an extensive range of new issues in preclinical research. MPI nicely complements Bruker’s preclinical imaging product portfolio of now nine different modalities. The highly sensitive visualization of functional characteristics in vivo at high temporal resolution offers great potential for small animal imaging, especially when combined with high spatial resolution morphological MRI."

"Magnetic particle imaging represents a fundamentally new imaging modality with an exceptional ability to image in vivo functional behavior," said Homer Pien, chief technology officer at Philips. "We are particularly excited about its potential for providing new insights into cardiovascular disease, cancer, and stem cell therapies. Going forward, I am convinced that the results from the research studies conducted with preclinical MPI systems will provide valuable guidance for our ongoing development of a whole-body clinical MPI system."

Related Links:
Bruker
Royal Philips


Channels

Genomics/Proteomics

view channel
Image: In mice, mitochondria (green) in healthy (left) and Mfn1-deficient heart muscle cells (center) are organized in a linear arrangement, but the organelles are enlarged and disorganized in Mfn2-deficient cells (right) (Photo courtesy of the Rockefeller Press).

Cell Biologists Find That Certain Mitochondrial Diseases Stem from Coenzyme Q10 Depletion

A team of German cell biologists has linked the development of certain mitochondrial-linked diseases to depletion of the organelles' pool of coenzyme Q10 brought about by mutation in the MFN2 gene, which... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.